Plus Therapeutics (PSTV)
NASDAQ:PSTV
Want to see PSTV full AI Analyst Report?
PSTV Stock Chart & Stats
$0.58
-$0.05(-4.03%)
At close: 4:00 PM EST
$0.58
-$0.05(-4.03%)
Day’s Range― - ―
52-Week Range$2.90 - $23.44
Previous CloseN/A
Volume69.06K
Average Volume (3M)223.44K
Market Cap
$44.26M
Enterprise Value$13.26M
Total Cash (Recent Filing)$3.02M
Total Debt (Recent Filing)$725.00K
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Aug 19, 2026EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-417.08
Shares Outstanding6,883,106
10 Day Avg. Volume170,510
30 Day Avg. Volume223,439
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)9.98
Price to Sales (P/S)7.65
P/FCF Ratio-1.91
Enterprise Value/Market Cap0.30
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit2.76
Enterprise Value/Ebitda-1.58
Forecast
1Y Price Target
$38.00Price Target Upside6451.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.87
Revenue Forecast (FY)$6.04M
Bulls Say, Bears Say
Bulls Say
Diagnostic Performance And Platform ExpansionCNSide's substantially higher sensitivity versus standard cytology, ability to detect actionable biomarkers, and plans to add next-generation sequencing and FISH assays should increase the test's clinical utility and appeal to physicians.
Financial RunwayRecent equity financing combined with existing cash resources provides operational runway to support ongoing clinical development and commercialization efforts for the CNSide platform.
Payer CoverageNew national payer agreements with insurers such as Highmark, UnitedHealthcare, and Humana expand reimbursement for the CNSide test and should broaden patient access to support wider clinical adoption.
Bears Say
Dilution And LiquidityPublic equity offerings and a reverse stock split increased dilution and reduced liquidity, elevating capital risk and potentially raising the company's cost of capital for future funding needs.
Execution And Valuation RiskValuation and outlook are exposed to multiple execution risks including possible clinical setbacks, commercial challenges, partnership disputes, financial constraints, and intellectual property issues that could weigh on the stock.
Regulatory Endpoint UncertaintyFDA indications that circulating tumor cells may not suffice as a primary surrogate endpoint raise the need for more rigorous clinical outcomes such as overall survival or quality-of-life measures, complicating approval pathways.
Plus Therapeutics News
PSTV FAQ
What was Plus Therapeutics’s price range in the past 12 months?
Plus Therapeutics lowest stock price was $2.90 and its highest was $23.44 in the past 12 months.
What is Plus Therapeutics’s market cap?
Plus Therapeutics’s market cap is $44.26M.
When is Plus Therapeutics’s upcoming earnings report date?
Plus Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 81 days.
How were Plus Therapeutics’s earnings last quarter?
Plus Therapeutics released its earnings results on Apr 16, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.848 by -$0.202.
Is Plus Therapeutics overvalued?
According to Wall Street analysts Plus Therapeutics’s price is currently Undervalued.
Does Plus Therapeutics pay dividends?
Plus Therapeutics does not currently pay dividends.
What is Plus Therapeutics’s EPS estimate?
Plus Therapeutics’s EPS estimate is -0.9.
How many shares outstanding does Plus Therapeutics have?
Plus Therapeutics has 6,883,106 shares outstanding.
What happened to Plus Therapeutics’s price movement after its last earnings report?
Plus Therapeutics reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.848. Following the earnings report the stock price went up 5.31%.
Which hedge fund is a major shareholder of Plus Therapeutics?
Currently, no hedge funds are holding shares in PSTV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Plus Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.00 (6451.72% Upside)
$38.00 (6451.72% Upside)
Blogger Sentiment
Bullish
PSTV Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.78%
12-Months-Change
Fundamentals
Return on Equity
-198.48%
Trailing 12-Months
Asset Growth
65.20%
Trailing 12-Months
Company Description
Plus Therapeutics
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
PSTV Stock 12 Month Forecast
Average Price Target
$38.00
▲(6451.72% Upside)
Technical Analysis
Karyopharm Therapeutics
―
Tvardi Therapeutics
―
Barinthus Biotherapeutics
―
Senti Biosciences
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
15.34% Insiders
0.04% Mutual Funds
― Other Institutional Investors
49.36% Public Companies and Individual Investors
Options Prices
Currently, No data available
---